Author:
Forlenza Orestes V.,Diniz Breno S.,Radanovic Márcia,Santos Franklin S.,Talib Leda L.,Gattaz Wagner F.
Abstract
BackgroundTwo recent clinical studies support the feasibility of trials to evaluate
the disease-modifying properties of lithium in Alzheimer's disease,
although no benefits were obtained from short-term treatment.AimsTo evaluate the effect of long-term lithium treatment on cognitive and
biological outcomes in people with amnestic mild cognitive impairment
(aMCI).MethodForty-five participants with aMCI were randomised to receive lithium
(0.25–0.5 mmol/l) (n = 24) or placebo
(n = 21) in a 12-month, double-blind trial. Primary
outcome measures were the modification of cognitive and functional test
scores, and concentrations of cerebrospinal fluid (CSF) biomarkers
(amyloid-beta peptide (Aβ42), total tau (T-tau),
phosphorylated-tau) (P-tau). Trial registration: NCT01055392.ResultsLithium treatment was associated with a significant decrease in CSF
concentrations of P-tau (P = 0.03) and better
perform-ance on the cognitive subscale of the Alzheimer's Disease
Assessment Scale and in attention tasks. Overall tolerability of lithium
was good and the adherence rate was 91%.ConclusionsThe present data support the notion that lithium has disease-modifying
properties with potential clinical implications in the prevention of
Alzheimer's disease.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Cited by
315 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献